Island Pharmaceuticals Ltd (AU:ILA)
ASX:ILA
Want to see AU:ILA full AI Analyst Report?
Top Page
Island Pharmaceuticals Ltd
(Sydney:ILA)
Select Model
Select Model
Rating:48Neutral
Price Target:
AU$0.35
▼(-20.23% Downside)
Action:Reiterated
Date:05/20/26
The score is held down primarily by weak operating performance (sharp revenue decline, deep losses) and ongoing cash burn, which increase financing risk despite a low-debt structure. Technicals are mixed with only modest near-term improvement and a still-weak longer-term trend. Valuation is constrained by negative earnings and no dividend yield data.
Positive Factors
Balance sheet strength
Zero reported debt and materially higher equity provide durable solvency benefits: lower default risk, greater flexibility to pursue clinical programs, and improved ability to negotiate non-dilutive partnerships or debt on favorable terms, supporting operations through development milestones.
Negative Factors
Sharp revenue decline
A ~70% year‑over‑year revenue drop signals weak or lumpy commercial traction or milestone timing issues; this materially reduces internal funding capacity, heightens dependence on external capital, and increases execution risk for sustaining development programs over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Zero reported debt and materially higher equity provide durable solvency benefits: lower default risk, greater flexibility to pursue clinical programs, and improved ability to negotiate non-dilutive partnerships or debt on favorable terms, supporting operations through development milestones.
Read all positive factors
Island Pharmaceuticals Ltd (ILA) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$108.01M
Dividend YieldN/A
Average Volume (3M)781.24K
Price to Earnings (P/E)―
Beta (1Y)-0.90
Revenue GrowthN/A
EPS Growth-9.57%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding295,916,700
10 Day Avg. Volume388,484
30 Day Avg. Volume781,243
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)3.39
Price to Sales (P/S)204.10
P/FCF Ratio-8.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Island Pharmaceuticals Ltd Business Overview & Revenue Model
Company Description
Island Pharmaceuticals Limited functions as a pharmaceutical enterprise dedicated to drug discovery and repurposing, with a specific focus on creating preventative or therapeutic solutions for viral infections. Its lead therapeutic agent, ISLA-101...
How the Company Makes Money
null...
Island Pharmaceuticals Ltd Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
66
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.07K | 118.91K | 1.25M | 11.06K | 0.00 | 0.00 |
| Gross Profit | -729.59K | -1.29M | -1.01M | 11.06K | 0.00 | 0.00 |
| EBITDA | -7.37M | -4.07M | -2.82M | -2.82M | -2.61M | -2.13M |
| Net Income | -7.20M | -3.92M | -2.86M | -2.83M | -2.61M | -2.13M |
Balance Sheet | ||||||
| Total Assets | 8.02M | 7.49M | 2.56M | 2.05M | 4.90M | 6.64M |
| Cash, Cash Equivalents and Short-Term Investments | 6.87M | 7.25M | 1.66M | 2.00M | 4.79M | 6.46M |
| Total Debt | 0.00 | 0.00 | 421.97K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 860.15K | 336.43K | 1.05M | 263.85K | 580.73K | 236.83K |
| Stockholders Equity | 7.16M | 7.16M | 1.52M | 1.79M | 4.32M | 6.40M |
Cash Flow | ||||||
| Free Cash Flow | -3.67M | -2.77M | -3.16M | -2.71M | -1.88M | -938.24K |
| Operating Cash Flow | -3.67M | -2.77M | -3.16M | -2.71M | -1.88M | -938.24K |
| Investing Cash Flow | -841.70K | 0.00 | 0.00 | 0.00 | 0.00 | 77.37K |
| Financing Cash Flow | 7.41M | 8.36M | 2.79M | -171.36K | 0.00 | 7.30M |
Island Pharmaceuticals Ltd Technical Analysis
Negative
0.44
Price Trends
0.37
Negative
0.38
Negative
0.41
Negative
Market Momentum
>-0.01
Positive
46.51
Neutral
46.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ILA, the sentiment is Negative. The current price of 0.44 is above the 20-day moving average (MA) of 0.38, above the 50-day MA of 0.37, and above the 200-day MA of 0.41, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.51 is Neutral, neither overbought nor oversold. The STOCH value of 46.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ILA.
Island Pharmaceuticals Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$71.50M | -7.81 | -62.49% | ― | ― | -13.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$108.01M | -13.02 | -100.58% | ― | ― | -9.57% | |
48 Neutral | AU$94.53M | -22.02 | -142.30% | ― | -45.25% | 40.54% | |
47 Neutral | AU$294.65M | -90.75 | -15.96% | ― | 364.97% | 74.50% | |
42 Neutral | AU$63.30M | -0.53 | -179.37% | ― | ― | 24.59% | |
42 Neutral | AU$25.72M | -6.80 | -19.10% | ― | ― | -285.37% |
* Healthcare Sector Average
AU:ILA
Island Pharmaceuticals Ltd
0.36
0.21
153.57%
AU:CYP
Cynata Therapeutics Limited
0.02
-0.14
-88.75%
AU:PTX
Prescient Therapeutics Limited
0.07
0.02
44.68%
AU:SPL
Starpharma Holdings Limited
0.70
0.61
708.14%
AU:ADO
AnteoTech Ltd
0.03
0.02
166.67%
AU:NSB
Neuroscientific Biopharmaceuticals Ltd.
0.06
-0.03
-31.11%
Island Pharmaceuticals Ltd Corporate Events
Island Pharmaceuticals Wins FDA Orphan Status for Marburg Antiviral Galidesivir
Jun 16, 2026
Island Pharmaceuticals has secured a significant regulatory boost with the U.S. Food and Drug Administration granting Orphan Drug Designation to its antiviral candidate Galidesivir for post-exposure prophylaxis of Marburg virus disease. The status...
Island Pharmaceuticals Showcases New PROTECT Study Data at Asia Dengue Summit
Jun 16, 2026
Island Pharmaceuticals Ltd, an Australian antiviral drug developer listed on the ASX, is concentrating on therapies for urgent viral diseases and biosecurity threats through its ISLA-101 and Galidesivir programs. ISLA-101 is being repurposed for d...
Island Pharmaceuticals expands US army research pact to advance Marburg antiviral
Jun 9, 2026
Island Pharmaceuticals has expanded its Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases and The Geneva Foundation, securing access to USAMRIID’s Biosafety Level 4 facilities...
Island Pharmaceuticals advances Galidesivir with new GMP manufacturing deal
Jun 3, 2026
Island Pharmaceuticals has engaged global contract research, development and manufacturing group PI Health Sciences to undertake a GMP manufacturing campaign for its lead antiviral Galidesivir. The program includes analytical method validation, re...
Island Pharma hires ex-BioCryst leader to accelerate Galidesivir biodefence push
May 21, 2026
Island Pharmaceuticals has appointed former BioCryst Pharmaceuticals executive Raymond Taylor as Senior Scientific Fellow to advance its lead antiviral, Galidesivir, particularly for Marburg Virus Disease under the U.S. FDA’s Animal Rule pat...
Island Pharmaceuticals Issues New Shares on Option Exercise, Affirms Regulatory Compliance
Apr 27, 2026
Island Pharmaceuticals has issued 335,000 fully paid ordinary shares following the exercise of unlisted options at an issue price of $0.21 per share, expanding its share capital without undertaking a separate disclosure document. The company confi...
Island Pharmaceuticals Seeks ASX Quotation for 335,000 New Shares
Apr 27, 2026
Island Pharmaceuticals has applied for quotation on the ASX of 335,000 new ordinary fully paid shares, with an issue date of April 27, 2026. The additional securities, arising from the exercise or conversion of existing instruments, modestly expan...
Island Pharmaceuticals secures FDA alignment and funding to advance Galidesivir biodefence program
Apr 26, 2026
Island Pharmaceuticals reported significant progress in the March quarter in advancing Galidesivir, securing clear alignment from the U.S. Food and Drug Administration on the drug’s Animal Rule development pathway and validation of its Marbu...
Island Pharmaceuticals Issues New Shares on Option Exercise, Affirms Regulatory Compliance
Mar 30, 2026
Island Pharmaceuticals has issued 125,000 fully paid ordinary shares following the exercise of unlisted options at an issue price of $0.21 per share, expanding its share capital without undertaking a new disclosure document. The company stated it ...
Island Pharmaceuticals Seeks Quotation for Additional 125,000 ASX Shares
Mar 30, 2026
Island Pharmaceuticals has applied to the ASX for quotation of an additional 125,000 ordinary fully paid shares, to be issued on March 30, 2026. The modest increase in quoted securities, arising from the exercise or conversion of existing instrume...
Island Pharmaceuticals Issues New Shares on Option Conversion, Affirms Compliance
Mar 22, 2026
Island Pharmaceuticals has issued 690,000 fully paid ordinary shares following the exercise of unlisted options at an issue price of $0.21 per share. The move modestly increases the company’s share capital and reflects the conversion of exis...
Island Pharmaceuticals Seeks ASX Quotation for 690,000 New Shares
Mar 22, 2026
Island Pharmaceuticals Ltd has applied for quotation on the ASX of 690,000 new ordinary fully paid shares, to be traded under its existing ticker ILA. The new securities, issued on March 23, 2026, modestly expand the company’s listed share b...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.